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Background
The East Asian variant of mitochondrial aldehyde dehy-
drogenase (ALDH2) exhibits significantly reduced dehy-
drogenase, esterase and nitroglycerin (GTN) reductase
activities [1]. The small molecule Alda-1 was reported to
partly restore low acetaldehyde dehydrogenase activity of
this variant [2]. In the present study we compared the wild
type enzyme (ALDH2*1) with the East Asian variant
(ALDH2*2) regarding GTN bioactivation and effects of
Alda-1.
Results
Alda-1 increased acetaldehyde oxidation by ALDH2*1
and ALDH2*2 about 2- and 15-fold, respectively. The
effects of this compound on the esterase activities of both
enzymes were identical to that of NAD (6- and 10-fold
stimulation with ALDH2*1 and ALDH2*2, respectively),
but in the presence of the nicotinamide Alda-1 stimulated
the esterase activity of ALDH2*1 only 1.7-fold, whereas
the ALDH2*2-catalyzed reaction was increased 73-fold.
ALDH2*1 exhibited a greater affinity for GTN than
ALDH2*2 (with Km values of 7.6 ± 1.4 and 54 ± 6 μM,
respectively) as well as a 7-fold higher maximal GTN den-
itration activity. However, bioactivation of the nitrate,
measured as soluble guanylate cyclase (sGC) activation,
was much more pronounced (8.8 ± 0.2 and 18.2 ± 0.9
μmol cGMP × min-1 × mg-1 in the presence of 100 μg/100
μL ALDH2 and 100 μM GTN). Alda-1 caused 30–70%
inhibition of GTN denitration by ALDH2*1 but had no
effect on the ALDH2*2-catalyzed reaction and did not
affect GTN-induced sGC activation in the presence of
either variant.
Conclusion
The present results indicate that Alda-1 stimulates estab-
lished ALDH2 activities by improving NAD binding but
does not restore impaired GTN bioactivation by the East
Asian variant. In addition, our data revealed an unex-
pected discrepancy between GTN reductase activity and
sGC activation, suggesting that GTN denitration and bio-
activation reflect independent reactions catalyzed by
ALDH2.
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